Advertisement

Diabetic Connect is a free online community to help you:

Get support from friends who really understand.
Learn about treatments from experts and members.
Share only what you want with complete privacy controls.

Join Now or Learn More About Diabetic Connect Smiling-faces

More Delays on MannKind's Inhaled Insulin: The Pros and Cons

Categories-bubble By BNet.com Categories-views 51 views Categories-time March 18 at 3:31 pm

Amy Tenderich

Biotech company MannKind (MNKD)’s tumultuous quest for approval of its inhaled insulin drug Afrezza has attracted outspoken supporters and detractors — and this week’s complete response letter from the FDA has them at each other’s throats again.

Read the full article at bnet.com Bullet-go

I like this I don't like this
  • Report Report as inappropriate
  • Share
    Email Email
    Print Print Twitter Twitter
    Facebook Facebook

Comments (No comments)

Add your comment Reply-down

Ask questions, get answers.
Give the community your two cents.
Be the first by adding your comments.

Advertisement

Advertisement